Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Kyle Mikson | Canaccord Genuity | 7 (0%) |
| Vijay Kumar | Evercore ISI | 7 (14%) |
| Tycho Peterson | Jefferies | 7 (71%) |
| Subha Nambi | Guggenheim | 7 (0%) |
| Puneet Souda | Leerink Partners | 6 (0%) |
| Doug Schenkel | Wolfe Research | 6 (17%) |
| Jack Meehan | Operon Research | 5 (0%) |
| David Westenberg | Piper Sandler | 4 (0%) |
| Dan Arias | Stifel | 4 (0%) |
| Dan Brennan | TD Cowen | 4 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Evercore ISI | 1 | 7 (14%) |
| Jefferies | 1 | 7 (71%) |
| Canaccord Genuity | 1 | 7 (0%) |
| Guggenheim | 1 |
| 7 (0%) |
| Wolfe Research | 1 | 6 (17%) |
| Leerink Partners | 1 | 6 (0%) |
| JPMorgan | 2 | 5 (0%) |
| Operon Research | 1 | 5 (0%) |
Illumina started 2026 strongly, with first-quarter revenue of $1.09 billion up 4.8% year-over-year (1.2% organic; Rest of World organic +3.5%) and non-GAAP EPS of $1.15 up approximately 19%, both above guidance. Clinical consumables grew 20% ex-China for the second consecutive quarter and made up more than 65% of sequencing consumables, while research and applied consumables fell 12% ex-China amid continued funding caution. Instrument demand was a standout, with over 80 NovaSeq X placements (about 20 more than Q1 2025) leaving the company supply-constrained and prompting a raise to the full-year instrument outlook. Management raised FY2026 revenue guidance to $4.52 billion to $4.62 billion and non-GAAP EPS to $5.15 to $5.30, expanded the buyback by $1.5 billion, and completed the SomaLogic acquisition, which is tracking to plan.
Demand | Product Launch | Guidance Reliability | Revenue Growth | Competitive Dynamics | Geographic Expansion | Margin | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 4 |
| 2025Q1 | 4 | 1 | 1 | 3 | 2 | |||
| 2025Q2 | 4 | 2 | 5 | 3 | 2 | 1 | ||
| 2025Q3 | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 1 |
| 2025Q4 | 5 | 4 | 2 | 3 | 2 | 1 | 1 | 1 |
| 2026Q1 | 4 | 7 | 3 | 5 | 4 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 3 | 4 | 4 | 4 | 5 | 4 |
| Product Launch | 2 | 2 | 4 | 4 | 7 | |
| Guidance Reliability | 1 | 1 | 5 | 4 | 2 | 3 |
| Revenue Growth | 1 | 1 | 3 | 3 | 3 | 5 |
| Competitive Dynamics | 1 | 3 | 2 | 1 | 2 | 4 |
| Geographic Expansion | 2 | 2 | 1 | 1 | 1 | |
| Margin | 2 | 2 | 1 | 2 | ||
| Regulation Policy | 4 | 1 | 1 |
What ILMN and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“As part of our growth in specialty areas, we're collaborating with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings.”
Labcorp is collaborating with Illumina to broaden genomic-testing access in oncology, a channel read-through for Illumina.
“During the quarter, we closed the acquisition of SomaLogic on January 30 for a net cash payment of $363 million plus potential royalties and milestone payments.”
Illumina closed the SomaLogic acquisition for a net cash payment of $363M; the business is performing in line with revenue and profitability expectations.
“I also enjoyed the launch of what 10x put out there.”
Illumina’s CEO praises 10x Genomics’ recent spatial-biology launch, framing it as expanding overall interest in the spatial market Illumina also serves.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.10B | -1.6% | $1.17 | +205.4% | 18.3% | 16.9% | $335M |
| FY2025 Q1 | $1.04B | -3.3% | $0.82 | +203.8% | 17.7% | 12.6% | $201M |
| FY2025 Q2 | $1.06B | -4.9% | $1.50 | +112.0% | 21.0% | 22.2% | $211M |
| FY2025 Q3 | $1.08B | +0.3% | $0.97 | -78.0% | 21.3% | 13.9% | $260M |
| FY2025 Q4 | $1.16B | +5.1% | $2.17 | +85.5% | 22.2% | 28.8% | $267M |
| FY2026 Q1 | $1.09B | +4.8% | $0.87 | +6.1% | 19.2% | 12.3% | $251M |
| FY2026 Q2 | $1.16B | +9.6% | $1.35 | -10.0% | 21.1% | 17.9% | $161M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 30, 2026
FY2026 Q1 in brief
Illumina started 2026 strongly, with first-quarter revenue of $1.09 billion up 4.8% year-over-year (1.2% organic; Rest of World organic +3.5%) and non-GAAP EPS of $1.15 up approximately 19%, both above guidance.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +4.80% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Illumina, Inc. (ILMN), FY2026 Q1: 8/10. Scores: Illumina, Inc.’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ILMN daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ILMN Illumina, Inc. | 8 | +4.8% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |